FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for KAZANO, a fixed-dose combination of alogliptin and metformin hydrochloride, by Takeda Pharmaceuticals America, I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• KAZANO (alogliptin and metformin hydrochloride)

Snippet

SUPPL AP for KAZANO (ALOGLIPTIN AND METFORMIN HYDROCHLORIDE)